{"DataElement":{"publicId":"4337095","version":"1.1","preferredName":"Initial Disease or Disorder Diagnosis MedDRA Code","preferredDefinition":"The MedDRA code number for the diagnosis of the initial state of a disease.","longName":"INI_DZ_DX_MEDDRA_CD","context":"PBTC","contextVersion":"1","DataElementConcept":{"publicId":"4337091","version":"1","preferredName":"Initial Disease or Disorder Diagnosis","preferredDefinition":"Information related to initial disease diagnosis.","longName":"4289612v1.0:2239981v1.0","context":"PBTC","contextVersion":"1","ObjectClass":{"publicId":"4289612","version":"1","preferredName":"Initial Disease or Disorder","preferredDefinition":"occurring at the beginning.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"CL052284:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Initial","conceptCode":"CL052284","definition":"occurring at the beginning.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F89F0D0F-5546-B50A-E040-BB89AD433CEC","latestVersionIndicator":"Yes","beginDate":"2014-05-04","endDate":null,"createdBy":"SWEW","dateCreated":"2014-05-04","modifiedBy":"ONEDATA","dateModified":"2014-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239981","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-1C71-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-26","modifiedBy":"ONEDATA","dateModified":"2005-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA7BA5A1-CC68-F69D-E040-BB89AD4342CD","latestVersionIndicator":"Yes","beginDate":"2014-05-28","endDate":null,"createdBy":"SWEW","dateCreated":"2014-05-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"PBTC_WMS_052814","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3292828","version":"1","preferredName":"MedDRA Code","preferredDefinition":"a system of numbered categories for an international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle.","longName":"3292828v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"10030139","valueDescription":"Esophagus","ValueMeaning":{"publicId":"3292829","version":"1","preferredName":"Esophagus","longName":"3292829","preferredDefinition":"The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophagus","conceptCode":"C12389","definition":"The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEB9CA2C-44A4-D4C6-E040-BB89AD432205","latestVersionIndicator":"Yes","beginDate":"2011-10-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEB9CA2C-4509-D4C6-E040-BB89AD432205","beginDate":"2011-10-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-07","modifiedBy":"ONEDATA","dateModified":"2011-10-07","deletedIndicator":"No"},{"value":"10027410","valueDescription":"Mesothelioma","ValueMeaning":{"publicId":"3292894","version":"1","preferredName":"Mesothelioma","longName":"3292894","preferredDefinition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesothelioma","conceptCode":"C3234","definition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEB9CA2C-4514-D4C6-E040-BB89AD432205","latestVersionIndicator":"Yes","beginDate":"2011-10-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEB9CA2C-452C-D4C6-E040-BB89AD432205","beginDate":"2011-10-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-07","modifiedBy":"ONEDATA","dateModified":"2011-10-07","deletedIndicator":"No"},{"value":"10052747","valueDescription":"Pancreas","ValueMeaning":{"publicId":"3297613","version":"1","preferredName":"Pancreas","longName":"3297613","preferredDefinition":"An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreas","conceptCode":"C12393","definition":"An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0262734-8F09-136C-E040-BB89AD433212","latestVersionIndicator":"Yes","beginDate":"2011-10-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-25","modifiedBy":"COOPERM","dateModified":"2018-04-05","changeDescription":"Updated concept definition to match current NCIt. 4.5.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0262734-8F21-136C-E040-BB89AD433212","beginDate":"2011-10-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-25","modifiedBy":"ONEDATA","dateModified":"2011-10-25","deletedIndicator":"No"},{"value":"10006285","valueDescription":"Breast cancer, NOS","ValueMeaning":{"publicId":"3442388","version":"1","preferredName":"Breast cancer, NOS","longName":"3442388","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE840591-091B-69F7-E040-BB89AD4368BA","latestVersionIndicator":"Yes","beginDate":"2012-04-25","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-04-25","modifiedBy":"ZHANGW","dateModified":"2021-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MedDRA:Medical Dictionary for Regulatory Affairs","id":"BE840591-0934-69F7-E040-BB89AD4368BA","beginDate":"2012-04-25","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-04-25","modifiedBy":"ONEDATA","dateModified":"2012-04-25","deletedIndicator":"No"},{"value":"10013806","valueDescription":"Ductal Carcinoma In Situ","ValueMeaning":{"publicId":"3262799","version":"1","preferredName":"Ductal Carcinoma In Situ","longName":"3262799","preferredDefinition":"A carcinoma entirely confined to the mammary ducts.  It is also known as DCIS.  There is no evidence of invasion of the basement membrane.  Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis.  The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma In Situ","conceptCode":"C2924","definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAB50210-A094-7298-E040-BB89AD4308A3","latestVersionIndicator":"Yes","beginDate":"2011-08-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1640086-57C2-FB58-E040-BB89AD434A33","beginDate":"2011-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-11-10","modifiedBy":"ONEDATA","dateModified":"2011-11-10","deletedIndicator":"No"},{"value":"10036910","valueDescription":"Prostate Carcinoma","ValueMeaning":{"publicId":"2596646","version":"1","preferredName":"Prostate Carcinoma","longName":"2596646","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2962D840-ED32-4EC3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BA977671-0BE1-9BE7-E040-BB89AD430711","beginDate":"2012-03-06","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-03-06","modifiedBy":"ONEDATA","dateModified":"2012-03-06","deletedIndicator":"No"},{"value":"10012820","valueDescription":"Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"3431650","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","longName":"3431650v1.00","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma._Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCE38D3C-F243-5CA3-E040-BB89AD4307F8","latestVersionIndicator":"Yes","beginDate":"2012-04-04","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-04-04","modifiedBy":"SOKKERL","dateModified":"2023-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MedDRA:Medical Dictionary for Regulatory Affairs","id":"BCE38D3C-F25B-5CA3-E040-BB89AD4307F8","beginDate":"2012-04-04","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-04-04","modifiedBy":"ONEDATA","dateModified":"2012-04-04","deletedIndicator":"No"},{"value":"100295154","valueDescription":"Lung Carcinoma","ValueMeaning":{"publicId":"2581279","version":"1","preferredName":"Lung Carcinoma","longName":"2581279","preferredDefinition":"A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B43B6E2B-6275-FD19-E040-BB89AD437374","beginDate":"2011-12-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-16","modifiedBy":"ONEDATA","dateModified":"2011-12-16","deletedIndicator":"No"},{"value":"10016896","valueDescription":"Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"2573076","version":"1","preferredName":"Non-Hodgkin Lymphoma","longName":"2573076","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA81-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9A83E25-AAB4-3207-E040-BB89AD4358C8","beginDate":"2012-02-23","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-02-23","modifiedBy":"ONEDATA","dateModified":"2012-02-23","deletedIndicator":"No"},{"value":"10033630","valueDescription":"Pancreatic Neuroendocrine Tumor","ValueMeaning":{"publicId":"3250495","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor","longName":"3250495","preferredDefinition":"A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Tumor","conceptCode":"C27720","definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6F215E6-C657-B293-E040-BB89AD432EF3","latestVersionIndicator":"Yes","beginDate":"2011-06-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9A3DDB0-7666-1600-E040-BB89AD432CFF","beginDate":"2012-02-23","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-02-23","modifiedBy":"ONEDATA","dateModified":"2012-02-23","deletedIndicator":"No"},{"value":"10041071","valueDescription":"Small Cell Lung Carcinoma","ValueMeaning":{"publicId":"3297699","version":"1","preferredName":"Small Cell Lung Carcinoma","longName":"3297699","preferredDefinition":"A highly aggressive subtype of lung carcinoma characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Small Cell Carcinoma","conceptCode":"C4917","definition":"A highly aggressive carcinoma with neuroendocrine differentiation arising from the lung. It is characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B035F07A-837C-9251-E040-BB89AD4303FC","latestVersionIndicator":"Yes","beginDate":"2011-10-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-26","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C2EABB63-3EAD-D0A9-E040-BB89AD43745C","beginDate":"2012-06-20","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-06-20","modifiedBy":"ONEDATA","dateModified":"2012-06-20","deletedIndicator":"No"},{"value":"10008960","valueDescription":"Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"2577156","version":"1","preferredName":"Chronic Lymphocytic Leukemia","longName":"2577156","preferredDefinition":"Chronic Lymphocytic Leukemia (CLL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA71-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ALAIS","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C9C26E4A-96AC-C30F-E040-BB89AD4337D4","beginDate":"2012-09-15","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-09-15","modifiedBy":"ONEDATA","dateModified":"2012-09-15","deletedIndicator":"No"},{"value":"10029514","valueDescription":"Lung Carcinoma","ValueMeaning":{"publicId":"2581279","version":"1","preferredName":"Lung Carcinoma","longName":"2581279","preferredDefinition":"A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEAF69C0-3454-7EE8-E040-BB89AD4375D0","beginDate":"2011-12-16","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-04-27","modifiedBy":"ONEDATA","dateModified":"2012-04-27","deletedIndicator":"No"},{"value":"10038415","valueDescription":"Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581668","version":"1","preferredName":"Renal Cell Carcinoma","longName":"2581668","preferredDefinition":"Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C11-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-09","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-09","modifiedBy":"ONEDATA","dateModified":"2006-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MedDRA:Medical Dictionary for Regulatory Affairs","id":"C2D887BB-F541-71D7-E040-BB89AD4337C3","beginDate":"2012-06-19","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-06-19","modifiedBy":"ONEDATA","dateModified":"2012-06-19","deletedIndicator":"No"},{"value":"10000884","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C640D6F8-DB19-597D-E040-BB89AD4304B1","beginDate":"2012-08-01","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-08-01","modifiedBy":"ONEDATA","dateModified":"2012-08-01","deletedIndicator":"No"},{"value":"10028534","valueDescription":"Myelodysplastic syndrome","ValueMeaning":{"publicId":"3118208","version":"1","preferredName":"Myelodysplastic syndrome","longName":"3118208","preferredDefinition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic syndrome","conceptCode":"E12552","definition":"A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AA8E6B0-1908-E859-E040-BB89AD433043","latestVersionIndicator":"Yes","beginDate":"2010-07-05","endDate":null,"createdBy":"DWARZEL","dateCreated":"2010-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C8E91D2E-7425-C37A-E040-BB89AD4307EB","beginDate":"2012-09-04","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-09-04","modifiedBy":"ONEDATA","dateModified":"2012-09-04","deletedIndicator":"No"},{"value":"10020255","valueDescription":"Hodgkin Lymphoma","ValueMeaning":{"publicId":"2573074","version":"1","preferredName":"Hodgkin Lymphoma","longName":"2573074","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of large tumor cells in an abundant admixture of nonneoplastic cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA7F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"TAYLORT","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C47F0980-F3BF-7CCC-E040-BB89AD4368C8","beginDate":"2012-07-10","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-07-10","modifiedBy":"ONEDATA","dateModified":"2012-07-10","deletedIndicator":"No"},{"value":"10049010","valueDescription":"Hepatocellular Carcinoma","ValueMeaning":{"publicId":"3187599","version":"1","preferredName":"Hepatocellular Carcinoma","longName":"3187599","preferredDefinition":"Pertaining to or affecting liver cells.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular","conceptCode":"C79753","definition":"Pertaining to or affecting liver cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9ADF8BBD-3572-8F43-E040-BB89AD436027","latestVersionIndicator":"Yes","beginDate":"2011-01-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-27","modifiedBy":"ONEDATA","dateModified":"2011-01-27","changeDescription":"03/27/2007 - Updated with NCI Thesaurus definition (abbreviated version.)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MedDRA:Medical Dictionary for Regulatory Affairs","id":"C47F0980-F3D3-7CCC-E040-BB89AD4368C8","beginDate":"2012-07-10","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-07-10","modifiedBy":"ONEDATA","dateModified":"2012-07-10","deletedIndicator":"No"},{"value":"10009951","valueDescription":"Colon Carcinoma","ValueMeaning":{"publicId":"3475567","version":"1","preferredName":"Colon Carcinoma","longName":"3475567","preferredDefinition":"A malignant tumor usually arising from the epithelium lining the large intestinal mucosa.  Colon carcinoma is one of the most common malignancies in both males and females, and is especially common in North America and Europe.  Grossly, most colon carcinomas are polypoid or ulcerating lesions. Microscopically, adenocarcinoma is the most frequently seen morphologic subtype.  Prognosis depends on the stage of the disease (depth of invasion, metastasis to regional/distal lymph nodes or other anatomic sites). -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colon Carcinoma","conceptCode":"C4910","definition":"A malignant epithelial neoplasm that arises from the colon and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1E80FC9-B780-A009-E040-BB89AD430688","latestVersionIndicator":"Yes","beginDate":"2012-06-07","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-06-07","modifiedBy":"ONEDATA","dateModified":"2012-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MedDRA:Medical Dictionary for Regulatory Affairs","id":"C1E80FC9-B799-A009-E040-BB89AD430688","beginDate":"2012-06-07","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-06-07","modifiedBy":"ONEDATA","dateModified":"2012-06-07","deletedIndicator":"No"},{"value":"10000846","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C535AF2F-7C4F-1195-E040-BB89AD436A83","beginDate":"2012-07-19","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-07-19","modifiedBy":"ONEDATA","dateModified":"2012-07-19","deletedIndicator":"No"},{"value":"10044409","valueDescription":"Transitional Cell Carcinoma","ValueMeaning":{"publicId":"3182041","version":"1","preferredName":"Transitional Cell Carcinoma","longName":"3182041","preferredDefinition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transitional Cell Carcinoma","conceptCode":"C2930","definition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9946BED9-27F0-40A8-E040-BB89AD43775F","latestVersionIndicator":"Yes","beginDate":"2011-01-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF794655-8FD8-8ADF-E040-BB89AD4321E5","beginDate":"2012-05-07","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-05-07","modifiedBy":"ONEDATA","dateModified":"2012-05-07","deletedIndicator":"No"},{"value":"10029268","valueDescription":"Neurofibromatosis","ValueMeaning":{"publicId":"2568792","version":"1","preferredName":"Neurofibromatosis","longName":"2568792","preferredDefinition":"A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibromatosis","conceptCode":"C6727","definition":"An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9C5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6901-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10029261","valueDescription":"Neuroblastoma","ValueMeaning":{"publicId":"2573075","version":"1","preferredName":"Neuroblastoma","longName":"2573075","preferredDefinition":"Neuroblastoma is a specific type of neuroblastic tumor which is characterized by the presense of neuroblastic cells forming groups or nests separated by delicate stromal septa without prominent Schwannian stroma. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA80-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6916-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10029208","valueDescription":"CNS-excluded nervous system cancer, NOS","ValueMeaning":{"publicId":"4339091","version":"1","preferredName":"CNS-excluded nervous system cancer, NOS","longName":"4339091","preferredDefinition":"The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.::1: The part of the nervous system that consists of the brain, spinal cord, and meninges.::2: The deliberate act of omission.::3: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nervous System","conceptCode":"C12755","definition":"The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Exclusion","conceptCode":"C82931","definition":"The deliberate act of omission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA902DE8-6920-3B83-E040-BB89AD432114","latestVersionIndicator":"Yes","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6939-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10035106","valueDescription":"Pituitary gland cancer, NOS","ValueMeaning":{"publicId":"4339092","version":"1","preferredName":"Pituitary gland cancer, NOS","longName":"4339092","preferredDefinition":"Pea-sized endocrine gland located at the base of the brain in the pituitary fossa. It produces and secretes hormones such as oxytocin and vasopressin, to regulate the activities of the hypothalamus.::1: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pituitary Gland","conceptCode":"C12399","definition":"Pea-sized endocrine gland located at the base of the brain in the pituitary fossa. It produces and secretes hormones such as oxytocin and vasopressin, to regulate the activities of the hypothalamus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA902DE8-6943-3B83-E040-BB89AD432114","latestVersionIndicator":"Yes","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-695C-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10011318","valueDescription":"Craniopharyngioma","ValueMeaning":{"publicId":"4265243","version":"1","preferredName":"Craniopharyngioma","longName":"4265243","preferredDefinition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniopharyngioma","conceptCode":"C2964","definition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-794B-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6970-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10030286","valueDescription":"Oligodendroglioma, NOS","ValueMeaning":{"publicId":"4339093","version":"1","preferredName":"Oligodendroglioma, NOS","longName":"4339093","preferredDefinition":"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA902DE8-697B-3B83-E040-BB89AD432114","latestVersionIndicator":"Yes","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6994-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10026659","valueDescription":"Anaplastic oligodendroglioma","ValueMeaning":{"publicId":"2572933","version":"1","preferredName":"Anaplastic oligodendroglioma","longName":"2572933","preferredDefinition":"A WHO grade III oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligodendroglioma","conceptCode":"C4326","definition":"A WHO grade 3 oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-69A8-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10027189","valueDescription":"Meningioma, NOS","ValueMeaning":{"publicId":"2573060","version":"1","preferredName":"Meningioma, NOS","longName":"2573060","preferredDefinition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA71-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-69BC-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10065853","valueDescription":"Nongerminomatous germ cell tumor of the CNS","ValueMeaning":{"publicId":"4339094","version":"1","preferredName":"Nongerminomatous germ cell tumor of the CNS","longName":"4339094","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.::1: Germ cell tumors of the central nervous system other than germinoma.  this category includes teratoma, choriocarcinoma, embryonal carcinoma, and yolk sac tumor.::2: A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Neoplasm","conceptCode":"C9293","definition":"A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Nongerminomatous Germ Cell Tumor","conceptCode":"C1000093","definition":"Germ cell tumors of the central nervous system other than germinoma.  this category includes teratoma, choriocarcinoma, embryonal carcinoma, and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Germ Cell Tumor","conceptCode":"C3708","definition":"A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA902DE8-69C6-3B83-E040-BB89AD432114","latestVersionIndicator":"Yes","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-69DF-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10065852","valueDescription":"Germinoma of CNS","ValueMeaning":{"publicId":"4339095","version":"1","preferredName":"Germinoma of CNS","longName":"4339095","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.::1: A malignant germ cell tumor arising in the central nervous system. It is characterized by the presence of primitive, large malignant germ cells and lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Neoplasm","conceptCode":"C9293","definition":"A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Germinoma","conceptCode":"C3753","definition":"A malignant germ cell tumor arising in the central nervous system. It is characterized by the presence of primitive, large malignant germ cells and lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA902DE8-69E9-3B83-E040-BB89AD432114","latestVersionIndicator":"Yes","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6A02-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10014967","valueDescription":"Ependymoma, NOS","ValueMeaning":{"publicId":"2573054","version":"1","preferredName":"Ependymoma, NOS","longName":"2573054","preferredDefinition":"A WHO grade II, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA6B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6A16-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10056672","valueDescription":"Supratentorial primitive neuroectodermal tumor","ValueMeaning":{"publicId":"2578697","version":"1","preferredName":"Supratentorial primitive neuroectodermal tumor","longName":"2578697","preferredDefinition":"A primitive and aggressive malignant neoplasm, usually arising from the cerebral hemispheres.  It is characterized by the presence of poorly differentiated or undifferentiated neuroepithelial cells.  This category includes tumors with exclusively neuronal differentiation which are termed cerebral neuroblastomas and tumors which contain ganglion cells and are termed ganglioneuroblastomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Supratentorial Embryonal Tumor, Not Otherwise Specified","conceptCode":"C6968","definition":"A central nervous system embryonal tumor, not otherwise specified arising from the supratentorial region.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0076-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6A2A-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10027107","valueDescription":"Medulloblastoma","ValueMeaning":{"publicId":"4265264","version":"1","preferredName":"Medulloblastoma","longName":"4265264","preferredDefinition":"A malignant, invasive embryonal neoplasm arising from the cerebellum. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, large cell medulloblastoma, and medulloblastoma with extensive nodularity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma","conceptCode":"C3222","definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4D75-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6A3E-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10065870","valueDescription":"Atypical teratoid/rhabdoid tumor","ValueMeaning":{"publicId":"4265197","version":"1","preferredName":"Atypical teratoid/rhabdoid tumor","longName":"4265197","preferredDefinition":"An aggressive malignant embryonal neoplasm arising from the central nervous system.  It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  It may be associated with loss of chromosome 22.  The vast majority of cases occur in childhood.  Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor","conceptCode":"C6906","definition":"An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68B0C53-8C4D-AAC5-E040-BB89AD436FF2","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6A53-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10035054","valueDescription":"Pineal parenchymal tumor","ValueMeaning":{"publicId":"4339096","version":"1","preferredName":"Pineal parenchymal tumor","longName":"4339096","preferredDefinition":"A neoplasm arising from the pineocyte, a cell with photosensory and neuroendocrine functions. It may be composed of mature elements or primitive, immature cells. The cellular composition determines the biological behavior and clinical outcome. Three types are recognized: pineoblastoma, pineocytoma, and pineal parenchymal tumor of intermediate differentiation (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineal Parenchymal Cell Neoplasm","conceptCode":"C6965","definition":"A neoplasm arising from the pineocyte, a cell with photosensory and neuroendocrine functions. It may be composed of mature elements or primitive, immature cells. The cellular composition determines the biological behavior and clinical outcome. Three types are recognized: pineoblastoma, pineocytoma, and pineal parenchymal tumor of intermediate differentiation (Adapted from WHO.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA902DE8-6A5E-3B83-E040-BB89AD432114","latestVersionIndicator":"Yes","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6A77-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10007959","valueDescription":"CNS primary tumor, NOS","ValueMeaning":{"publicId":"3325249","version":"1","preferredName":"CNS primary tumor, NOS","longName":"3325249","preferredDefinition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.::1: A tumor at the original site of origin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Primary Neoplasm","conceptCode":"C8509","definition":"A tumor at the original site of origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B38490CA-1639-A4CE-E040-BB89AD430D6C","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6A8B-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"90600120","valueDescription":"Choroid plexus carcinoma","ValueMeaning":{"publicId":"2578711","version":"1","preferredName":"Choroid plexus carcinoma","longName":"2578711","preferredDefinition":"Choroid Plexus Carcinoma (WHO grade III) is a malignant Choroid Plexus Tumor which shows anaplastic features and usually invades neighboring brain structures. CSF metastases are frequent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Carcinoma","conceptCode":"C4715","definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0084-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6AA0-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"90600112","valueDescription":"Pilocytic astrocytoma","ValueMeaning":{"publicId":"2578708","version":"1","preferredName":"Pilocytic astrocytoma","longName":"2578708","preferredDefinition":"Pilocytic Astrocytoma, the most common glioma in children, is a WHO grade I astrocytic tumor. It is a generally well circumscribed, slowly growing, often cystic, astrocytoma. It is histologically characterized by a biphasic pattern with varying proportion of compacted bipolar cells which may have Rosenthal fibers (tapered corkscrew-shaped, brightly eosinophilic, intracytoplasmic hyaline masses) and loose textured multipolar cells with microcysts and granular bodies. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilocytic Astrocytoma","conceptCode":"C4047","definition":"A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0081-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6AB4-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10003571","valueDescription":"Low-grade astrocytoma, NOS","ValueMeaning":{"publicId":"3325250","version":"1","preferredName":"Low-grade astrocytoma, NOS","longName":"3325250","preferredDefinition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.::1: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B38490CA-165C-A4CE-E040-BB89AD430D6C","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6AC8-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10065889","valueDescription":"Fibrillary astrocytoma","ValueMeaning":{"publicId":"2578707","version":"1","preferredName":"Fibrillary astrocytoma","longName":"2578707","preferredDefinition":"The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrillary Astrocytoma","conceptCode":"C4322","definition":"The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0080-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6ADD-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10008093","valueDescription":"Astrocytoma, NOS","ValueMeaning":{"publicId":"2837827","version":"1","preferredName":"Astrocytoma, NOS","longName":"2837827","preferredDefinition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"628169CF-83A0-F4D3-E040-BB89AD433D78","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"REEVESD","dateModified":"2014-07-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6AF1-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10018337","valueDescription":"Glioblastoma multiforme","ValueMeaning":{"publicId":"2831120","version":"1","preferredName":"Glioblastoma multiforme","longName":"2831120","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D4F-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6B05-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10006143","valueDescription":"Diffuse Brainstem Glioma","ValueMeaning":{"publicId":"3270787","version":"1","preferredName":"Diffuse Brainstem Glioma","longName":"3270787","preferredDefinition":"widely spread; not localized or confined.::1: A neuroglial tumor that arises from the brain stem.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse","conceptCode":"C14175","definition":"Widely spread; not localized or confined.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Brain Stem Glioma","conceptCode":"C8501","definition":"A glioma that arises from the brain stem.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC1CCA5-3F40-7039-E040-BB89AD431322","latestVersionIndicator":"Yes","beginDate":"2011-09-12","endDate":null,"createdBy":"SORENSENS","dateCreated":"2011-09-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6B19-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"10002224","valueDescription":"Anaplastic astrocytoma","ValueMeaning":{"publicId":"2572930","version":"1","preferredName":"Anaplastic astrocytoma","longName":"2572930","preferredDefinition":"A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Astrocytoma","conceptCode":"C9477","definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9EF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FA902DE8-6B2E-3B83-E040-BB89AD432114","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"ONEDATA","dateModified":"2014-05-29","deletedIndicator":"No"},{"value":"Breast Carcinoma","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"2581276","version":"1","preferredName":"Breast Carcinoma","longName":"2581276","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"47E19F82-655D-3A88-E053-F662850AB964","beginDate":"2012-04-25","endDate":"2012-04-26","createdBy":"HARTLEYG","dateCreated":"2017-02-06","modifiedBy":"ONEDATA","dateModified":"2017-02-06","deletedIndicator":"No"},{"value":"Prostate Carcinoma","valueDescription":"Prostate Carcinoma","ValueMeaning":{"publicId":"2596646","version":"1","preferredName":"Prostate Carcinoma","longName":"2596646","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2962D840-ED32-4EC3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"47E19F82-6575-3A88-E053-F662850AB964","beginDate":"2012-03-06","endDate":"2012-03-08","createdBy":"HARTLEYG","dateCreated":"2017-02-06","modifiedBy":"ONEDATA","dateModified":"2017-02-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3121582","version":"1","preferredName":"MedDRA Code","preferredDefinition":"An international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The MedDRA Maintenance and Support Services Organization holds a contract with the International Federation of Pharmaceutical Manufacturers Associations to maintain and support the implementation of the terminology.:A system of numbered categories for representation of data.","longName":"C43820:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MedDRA","conceptCode":"C43820","definition":"An international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The MedDRA Maintenance and Support Services Organization holds a contract with the International Federation of Pharmaceutical Manufacturers Associations to maintain and support the implementation of the terminology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B5D9360-9AE7-B147-E040-BB89AD4340CC","latestVersionIndicator":"Yes","beginDate":"2010-07-14","endDate":null,"createdBy":"BLKLDR","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEB9CA2C-448E-D4C6-E040-BB89AD432205","latestVersionIndicator":"Yes","beginDate":"2011-10-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-07","modifiedBy":"HARTLEYG","dateModified":"2017-02-06","changeDescription":"Added values for the central nervous system","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Initial Diagnosis","type":"Preferred Question Text","description":"Initial Diagnosis","url":null,"context":"PBTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39AA92F5-61B2-CEA8-E050-BB89AD435F9E","latestVersionIndicator":"Yes","beginDate":"2014-05-28","endDate":null,"createdBy":"SWEW","dateCreated":"2016-08-09","modifiedBy":"SWEW","dateModified":"2016-08-29","changeDescription":"PBTC_WMS_052814 8/9/16 wms - CDE was versioned to 1.1 to update the definition and Rave friendly short name.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}